ADMA Biologics Announces Closing of $57.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 25 2021 - 3:01PM
ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial
biopharmaceutical company dedicated to manufacturing, marketing and
developing specialty plasma-derived biologics, today announced the
closing of its previously announced underwritten public offering of
50 million shares of its common stock at a public offering price of
$1.00 per share, in addition to the exercise in full of the
underwriters’ option to purchase an additional 7.5 million shares
of common stock. The gross proceeds from the exercise of the
overallotment option were $7.5 million, bringing the total gross
proceeds to ADMA from the offering to $57.5 million, before
deducting underwriting discounts and commissions and other
estimated offering expenses.
ADMA intends to use the net proceeds from this offering (i) to
advance the commercial sales of its U.S. Food and Drug
Administration (FDA)-approved products through the procurement of
raw materials for the manufacturing of BIVIGAM® and ASCENIV™; (ii)
to expand its plasma collection facility network; (iii) to scale up
the manufacturing capacity of its Boca Raton facility and to make
continuous improvements in order to adhere to current Good
Manufacturing Practice (cGMP) compliance; (iv) to explore business
development opportunities; and (v) for general corporate purposes
and other capital expenditures.
Raymond James & Associates, Inc. and Cantor Fitzgerald &
Co. acted as joint book-running managers for the offering.
The offering of the securities described above was made by the
Company pursuant to a “shelf” registration statement on Form S-3
(File No. 333-256643) previously filed with the Securities and
Exchange Commission (“SEC”) and declared effective on August 3,
2021. The final prospectus supplement and the accompanying
prospectus relating to the offering was filed with the SEC on
October 21, 2021 and is available on the SEC’s website at
www.sec.gov. Electronic copies of the final prospectus supplement
and the accompanying prospectus relating to the offering may be
obtained from Raymond James & Associates, Inc., Attention:
Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida
33716, or by telephone at (800) 248-8863, or e-mail at
prospectus@raymondjames.com, or from Cantor Fitzgerald & Co.,
Attn: Capital Markets, 499 Park Avenue, 4th Floor, New York, New
York 10022 or by e-mail at prospectus@cantor.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any securities described herein,
nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About ADMA Biologics, Inc.
(ADMA)
ADMA Biologics is an end-to-end commercial
biopharmaceutical company dedicated to manufacturing, marketing and
developing specialty plasma-derived biologics for the treatment of
immunodeficient patients at risk for infection and others at risk
for certain infectious diseases. ADMA currently manufactures and
markets three United States Food and Drug Administration
(FDA)-approved plasma-derived biologics for the treatment of immune
deficiencies and the prevention of certain infectious diseases:
ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for
the treatment of primary humoral immunodeficiency (PI); BIVIGAM®
(immune globulin intravenous, human) for the treatment of PI; and
NABI-HB® (hepatitis B immune globulin, human) to provide enhanced
immunity against the hepatitis B virus. ADMA manufactures its
immune globulin products at its FDA-licensed plasma fractionation
and purification facility located in Boca Raton, Florida. Through
its ADMA BioCenters subsidiary, ADMA also operates as an
FDA-approved source plasma collector in the U.S., which provides a
portion of its blood plasma for the manufacture of its products.
ADMA’s mission is to manufacture, market and develop specialty
plasma-derived, human immune globulins targeted to niche patient
populations for the treatment and prevention of certain infectious
diseases and management of immune compromised patient populations
who suffer from an underlying immune deficiency, or who may be
immune compromised for other medical reasons. ADMA has received
U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and
10,259,865 related to certain aspects of its products and product
candidates. For more information, please visit
www.admabiologics.com.
Cautionary Note Regarding
Forward-Looking Statements
This press release contains “forward-looking
statements” pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995, about ADMA Biologics,
Inc. (“we,” “our” or the “Company”). Forward-looking statements
include, without limitation, any statement that may predict,
forecast, indicate, or imply future results, performance or
achievements, and may contain such words as “estimate,” “project,”
“intend,” “forecast,” “target,” “anticipate,” “plan,” “planning,”
“expect,” “believe,” “will,” “is likely,” “will likely,” “should,”
“could,” “would,” “may,” or, in each case, their negative, or words
or expressions of similar meaning. These forward-looking statements
include statements about ADMA’s intended use of proceeds generated
from the offering. Actual events or results may differ materially
from those described in this document due to a number of important
factors. Current and prospective security holders are cautioned
that there also can be no assurance that the forward-looking
statements included in this press release will prove to be
accurate. Except to the extent required by applicable laws or
rules, ADMA does not undertake any obligation to update any
forward-looking statements or to announce revisions to any of the
forward-looking statements. Forward-looking statements are subject
to many risks, uncertainties and other factors that could cause our
actual results, and the timing of certain events, to differ
materially from any future results expressed or implied by the
forward-looking statements, including, but not limited to, risks
and uncertainties related to market conditions and satisfaction of
customary closing conditions related to the public offering and the
risks and uncertainties described in our filings with the U.S.
Securities and Exchange Commission, including our most recent
reports on Form 10-K, 10-Q and 8-K, and any amendments thereto.
COMPANY CONTACT: Skyler
BloomDirector, Investor Relations and Corporate Strategy |
201-478-5552 | sbloom@admabio.com
INVESTOR RELATIONS
CONTACT:Michelle Pappanastos Senior Managing Director,
Argot Partners | 212-600-1902 | michelle@argotpartners.com
Adma Biologics (NASDAQ:ADMA)
Historical Stock Chart
From Apr 2024 to May 2024
Adma Biologics (NASDAQ:ADMA)
Historical Stock Chart
From May 2023 to May 2024